You have introduced the concept of progressive atherosclerotic burden to characterize the multiplicity of biologic, metabolic, and clinical markers in a CV risk profile. How do you apply this aggregated risk to patient selection for PCSK9 inhibitors?
You have introduced the concept of “progressive atherosclerotic burden” to characterize the multiplicity of biologic, metabolic, and clinical markers in a CV risk profile. How do you apply this “aggregated risk” to patient selection for PCSK9 inhibitors?
Created by
Presenter
Michael Davidson, MD, FACC, FACP, FNLA
Clinical Professor Director of Preventive Cardiology The University of Chicago Hospitals and Clinic Pritzker School of Medicine Chicago, Illinois